- Corporate
- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Privacy policy
- Contact us
- Subscribe
- Thank you
- Error
XPS™ sold to a leading lung transplant clinic in Europe
The clinic in Vienna has more than 30 years’ experience of lung transplantation and has a well-reputed lung transplant program for being a leader in the field of Ex Vivo Lung Perfusion (EVLP). Austria has the highest rate of lung transplants per million population (13.3) according to the Global Observatory on Donation and Transplantation. The Division of Thoracic Surgery in Vienna is a high volume lung transplant center with more than 100 transplantations per year.
The AKH University Hospital has previously performed EVLP with the manual method (without the XPS™) and for a period of time borrowed an XPS™. According to the Company’s business model, the pricing strategy for capital goods, that is the EVLP machines LS™ and XPS™, is so designed that sales of capital goods do not have a significant financial impact on the Company. According to the Company’s pricing strategy, future sales of STEEN Solution™ for use in the EVLP machines and accompanying single-use items are of financial significance for the Company.
“The company are especially pleased that the AKH University Hospital in Vienna has purchased an XPS™ since the clinic in Vienna is in the forefront of enlarging the use of donated lungs and has historically performed ground breaking science in this area," says Magnus Nilsson, CEO of XVIVO Perfusion.
May 19, 2020
Gothenburg
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on May 19, 2020.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.